stoxline Quote Chart Rank Option Currency Glossary
  
Dynavax Technologies Corporation (DVAX)
12.91  0.06 (0.47%)    12-11 16:00
Open: 12.88
High: 13.01
Volume: 857,950
  
Pre. Close: 12.85
Low: 12.8508
Market Cap: 1,697(M)
Technical analysis
2024-12-11 4:42:39 PM
Short term     
Mid term     
Targets 6-month :  16.22 1-year :  18.94
Resists First :  13.89 Second :  16.22
Pivot price 12.72
Supports First :  12.41 Second :  11.51
MAs MA(5) :  12.85 MA(20) :  12.68
MA(100) :  11.5 MA(250) :  11.97
MACD MACD :  0.2 Signal :  0.2
%K %D K(14,3) :  85.1 D(3) :  78.9
RSI RSI(14): 58.7
52-week High :  15.01 Low :  9.73
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ DVAX ] has closed below upper band by 30.7%. Bollinger Bands are 37.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 13.03 - 13.08 13.08 - 13.13
Low: 12.72 - 12.78 12.78 - 12.83
Close: 12.82 - 12.91 12.91 - 13
Company Description

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.

Headline News

Mon, 09 Dec 2024
Dynavax Technologies Co. (NASDAQ:DVAX) Shares Sold by Zurcher Kantonalbank Zurich Cantonalbank - MarketBeat

Sat, 07 Dec 2024
Dynavax Technologies Corporation (NASDAQ:DVAX) Q3 2024 Earnings Call Transcript - MSN

Wed, 27 Nov 2024
DVAX - Dynavax Technologies Corporation Latest Stock News & Market Updates - StockTitan

Tue, 26 Nov 2024
Dynavax Technologies to Present at Evercore HealthCONx Conference | DVAX Stock News - StockTitan

Tue, 26 Nov 2024
Dynavax to Present at the 7th Annual Evercore HealthCONx Conference - PR Newswire

Mon, 25 Nov 2024
Do Options Traders Know Something About Dynavax Technologies (DVAX) Stock We Don't? - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Shares Out 131 (M)
Shares Float 113 (M)
Held by Insiders 0.3 (%)
Held by Institutions 104.6 (%)
Shares Short 21,000 (K)
Shares Short P.Month 17,060 (K)
Stock Financials
EPS 0.15
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 5.19
Profit Margin 7.8 %
Operating Margin 15.2 %
Return on Assets (ttm) -0.4 %
Return on Equity (ttm) 3.1 %
Qtrly Rev. Growth 16 %
Gross Profit (p.s.) 0
Sales Per Share 1.98
EBITDA (p.s.) -0.02
Qtrly Earnings Growth 20.7 %
Operating Cash Flow 27 (M)
Levered Free Cash Flow 13 (M)
Stock Valuations
PE Ratio 86.06
PEG Ratio 0
Price to Book value 2.48
Price to Sales 6.5
Price to Cash Flow 62.23
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android